相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Kelly M. Quesnelle et al.
CLINICAL CANCER RESEARCH (2011)
Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites
Mei Zhao et al.
CLINICAL CANCER RESEARCH (2011)
Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells
Wei-Chien Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer
Manuel Hidalgo et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma
Gang Niu et al.
CLINICAL CANCER RESEARCH (2010)
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Zhan Yao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells
Andres Lopez-Albaitero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Positron Emission Tomography (PET) Imaging with [11C]-Labeled Erlotinib: A Micro-PET Study on Mice with Lung Tumor Xenografts
Ashfaque A. Memon et al.
CANCER RESEARCH (2009)
The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma
Tanguy Y. Seiwert et al.
CANCER RESEARCH (2009)
Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines
Yasmine Haddad et al.
CLINICAL CANCER RESEARCH (2009)
Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells
Sergio Benavente et al.
CLINICAL CANCER RESEARCH (2009)
From Human to Mouse and Back: Tumorgraft Models Surge in Popularity
Ken Garber
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Nuclear EGFR contributes to acquired resistance to cetuximab
C. Li et al.
ONCOGENE (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma - Predictive and prognostic correlation
Susan Muller et al.
CANCER (2008)
Head and neck cancer: Changing epidemiology, diagnosis, and treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Fumiyuki Yamasaki et al.
MOLECULAR CANCER THERAPEUTICS (2007)
iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors
L. V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
Mark Agulnik et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer:: The ONCOBELL trial
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Head and neck squamous cell carcinoma cell lines: Established models and rationale for selection
Charles J. Lin et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT
G. Studer et al.
ACTA ONCOLOGICA (2007)
Effects of smoking on the pharmacokinetics of erlotinib
M Hamilton et al.
CLINICAL CANCER RESEARCH (2006)
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study
FR Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Opinion - Profiling early head and neck cancer
KD Hunter et al.
NATURE REVIEWS CANCER (2005)
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy
F Ciardiello et al.
CLINICAL CANCER RESEARCH (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers
WJ Petty et al.
CLINICAL CANCER RESEARCH (2004)
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
D Soulieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
